Abstract
Budesonide orodispersible tablets (BOT) are the only approved pharmaceutical for the treatment of eosinophilic esophagitis (EoE) and the only reimbursed in-label option in Austria. This research aims to explore the cost-effectiveness of BOT versus a widely used dietary intervention, the six food elimination diet (SFED) since there are no other approved pharmaceuticals for EoE.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
